Switzerland

 

Bid may undervalue Mediclinic

South African analysts say the 504p per share, £3.7bn proposed cash offer for Mediclinic International's equity, the South African, Swiss and Middle East hospital group may somewhat undervalue the business. The current offer equates to an enterprise value of £5.88bn. Analysts put the break up value on an enterprise value at between £5.5bn and £6.2bn. HBI reckons the equity alone could be worth £5.2bn.
July 20, 2022

3R buys in Switzerland and looks at France

Naxicap-owned imaging group 3R Réseau Radiologique Romand has bought IRIS Radiologie and is eyeing up France. Germany and Italy are also possibles, HBI hears.
July 7, 2022

Swiss labs suffer 10% cut, more may follow

Switzerland has chopped its diagnostic lab prices by 10% in a move that is billed as saving CHf 140m (€141). There could well be further crackdowns following a publication highlighting the massive differences between Swiss prices and those in France, Germany and the Netherlands.
July 7, 2022

Mediclinic rejects £3.4bn takeover bid from consortium led by largest shareholder

Multinational South African hospital group Mediclinic has rejected a proposal for a possible cash offer of £3.4bn for the company’s entire share capital. The proposal came from a consortium comprising Mediclinic’s current largest shareholder, South African investment holding firm Remgro, and Mediterranean Shipping Company (MSC), the world’s second largest container shipping provider.
June 10, 2022

Swiss imaging and lab groups sigh with relief

A new outpatient tariff which would have taken 6-10% points off imaging prices has been kicked down the road for the third time by the byzantine Swiss healthcare system. It would have severely clipped the very high margins enjoyed by many whilst upping prices for primary care.
June 9, 2022

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.
April 28, 2022

Interview: Giuseppe Recchi, CEO, Affidea

In light of multinational diagnostic imaging provider Affidea's recent acquisition of Brust Zentrum, a Zurich-based breast cancer care provider, we speak to CEO Giuseppe Recchi about the company's vision to create a pan-European polydiagnostic outpatient platform.
April 21, 2022

Sanoptis sells to unexpected buyer

As predicted by HBI earlier this year, fast-growing German and Swiss ophthalmology group Sanoptis has sold - but to an unexpected buyer. Owner Telemos Capital has signed an agreement to sell to family-backed investment holding company Groupe Bruxelles Lambert (GBL), the same group which has also just agreed to buy a majority stake in European imaging and cancer treatment provider Affidea.
April 21, 2022

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.
April 19, 2022
Newer posts
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us